ENTITY
RemeGen

RemeGen (9995 HK)

312
Analysis
Health Care • China
RemeGen is a China-based biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on therapeutic antibody drugs, including antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies, for major diseases such as autoimmune disorders, oncology, and ophthalmology. Key products include Telitacicept (RC18) and Disitamab Vedotin (RC48). RemeGen was co-founded in 2008 and is headquartered in Yantai, Shandong Province, China.
more
•07 Jun 2026 10:00

A-H Premium Weekly (Jun 5th): Yankuang Energy, Haier Smarthome, Times Electric, China Coal, Ping An

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Yankuang Energy, Haier Smarthome, Times Electric, China...

Logo
138 Views
Share
•24 May 2026 10:15

A-H Premium Weekly (May 22nd): China Longyuan Power, Eastroc, CIMC, Remegen

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Longyuan Power, Eastroc, CIMC, Remegen.

Logo
91 Views
Share
•27 Apr 2026 23:18

Mabwell (迈威生物) A+H IPO Trading

​Mabwell A+H is set to start trading on April 28. We update deal dynamics, recap valuation, and reference peers. We think the deal will be...

Logo
224 Views
Share
•20 Apr 2026 17:55

Mabwell (迈威生物) A+H: Moderate Upside but Connect Event Ahead

Mabwell A+H: China biotech IPO with a near-term Phase III catalyst, but both lead indications face meaningful competitive headwinds. Moderate...

Logo
279 Views
Share
•19 Apr 2026 10:05

HK Connect Flows Weekly (Apr 17th): Pop Mart Intl, China Life, Tencent, Xiaomi, SMIC, YOFC, CCB

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Pop Mart Intl, China Life, Tencent, Xiaomi, SMIC, YOFC,...

Logo
231 Views
Share
x